

# Gemini Stock Analysis Report

---

Based on the provided **Stock Detailed Analysis Report for SUNPHARMA.NS** (generated 2026-01-24), here is my analysis and recommendation.

## Step 1: Audit the Data

### • Data Present:

- **Price Action:** Daily, Weekly, and 15-minute candlestick charts with EMA overlays (20, 50, 200).
- **Trend Indicators:** Supertrend, MACD, Moving Average Crossovers.
- **Momentum/Volatility:** RSI (with divergence analysis), Bollinger Bands, Volatility Squeeze/ATR.
- **Relative Strength:** RS Score and comparison against the sector benchmark (^CNXPHARMA).
- **Fundamental Snapshot:** Revenue/EPS trends and analyst estimates.
- **Volume:** Volume Analysis with distribution/accumulation days.

### • Data Missing:

- **Detailed Fibonacci Retracements:** While price levels are clear, explicit Fib levels from the 2024 lows to 2025 highs would help pinpoint deep support.
- **Option Chain Data:** Open Interest data is not provided, which would be useful for identifying institutional hurdles at strike prices like 1700.
- **Confidence Level: High.** The report provides a comprehensive technical suite sufficient for a positional trade decision. The "Current Date" is simulated as **January 24, 2026**.

## Step 2: Analyze the Setup

### Price Structure & Trend:

- **Bearish Reversal:** The stock is in a confirmed intermediate-term downtrend, characterized by lower highs and lower lows since late 2025.
- **Key Breakdown:** The price (1631.90) is currently trading below the **200-day EMA (1700.35)**. For a positional trader, being below the 200 EMA is a major red flag, indicating institutional distribution.
- **Resistance Cluster:** There is a heavy "lid" on the price between **1690 and 1720**, where the 20 EMA (1692), 200 EMA (1700), and 50 EMA (1717) are clustered. This zone will act as formidable dynamic resistance.

### Momentum & Strength:

- **RSI:** The RSI is at **32.07**. While this is technically "oversold" and could prompt a reflex bounce (dead cat bounce), RSI is not showing strong bullish divergence to justify a trend reversal yet.
- **Relative Strength:** The RS Score is **49.3/100** and "Weakening." The stock is underperforming its sector. We generally avoid buying laggards in positional trading.
- **Supertrend:** The status is **DOWNTREND (Sell)** across Weekly, Daily, and 15-minute timeframes.

### Volume & Volatility:

- **Volume:** Distribution days are dominating the recent history.
- **Bollinger Bands:** The price is hugging the lower band, and the "Squeeze" indicator (Page 15) suggests volatility is contracting. In a downtrend, a volatility squeeze often resolves in the direction of the trend (downwards).

## Step 3: Formulate the Recommendation

**Decision: NO.**

# Gemini Stock Analysis Report

---

**Reasoning:** I cannot recommend a Long entry at this time. The stock is a "falling knife" trading below the critical 200-day moving average. The probability of upside is low because any rally will likely face heavy selling pressure at the 1700-1720 resistance cluster. The setups are aligned for a continued correction or choppy consolidation, not the 5-15% impulse move we seek.

However, the stock is fundamentally sound (as per analyst targets), so we will watch for a structural repair.

## Conditional Plan (Watchlist Only):

We only become interested if the bulls regain control of the long-term trend.

- **Condition to Buy:** The stock must close decisively above the **50-day EMA (currently ~1717)** and reclaim the **200-day EMA (1700)**. This would confirm a "false breakdown" and trap the bears.
- **Entry Price:** INR 1735 (Buy Stop Order). We need a clear break above the 1720 resistance cluster to confirm momentum.
- **Stop Loss:** INR 1675 (Hard Stop). This places the risk just below the moving average cluster (which should flip to support after the breakout).
- **Take Profit:** INR 1860. This targets the previous swing highs from late 2025.
  - *Risk/Reward Ratio:* ~1:2 (Risking ~3.5% to make ~7.2%).

## News & Analyst Targets

**Date:** January 25, 2026 **To:** Investment Committee & Clients **From:** Equity Research Desk (Pharma & Healthcare) **Subject:** SUNPHARMA - Weekly Update & Actionable Insights

Here is the latest research update on Sun Pharmaceutical Industries Ltd. (SUNPHARMA) for the week ending January 25, 2026.

### 1) Latest News for SUNPHARMA (Week of Jan 19-25, 2026)

The week has been dominated by two major headlines: a significant product approval in the lucrative obesity market and a potential large-scale cross-border acquisition.

**DCGI Approval for Generic Wegovy (Semaglutide):** On Friday, January 23, 2026, Sun Pharma received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of **Semaglutide** (the active ingredient in Novo Nordisk's Wegovy/Ozempic) for chronic weight management.

- **Brand Name:** The product will be launched under the brand name '**Noveltreat**'.
- **Launch Timeline:** Launch is expected shortly after the patent expiry of the innovator drug in India in **March 2026**.
- **Details:** It will be available in a pre-filled pen in five dosage strengths. This follows the December 2025 approval of its diabetic version, 'Sematrinity'.

**Potential Acquisition of Organon:** Reports from January 23 indicate that Sun Pharma has submitted a non-binding proposal to acquire **Organon (NYSE: OGN)**.

- **Strategic Fit:** If completed, this would be the largest cross-border acquisition by an Indian pharma major, significantly expanding Sun's portfolio in **Women's Health** and **Biosimilars**.

# Gemini Stock Analysis Report

- **Market Reaction:** Organon stock saw strong momentum following the news; Sun Pharma investors are awaiting valuation details to assess balance sheet impact.

**Q3 FY26 Earnings Date Announcement:** The company officially announced that it will release its financial results for the quarter ended December 31, 2025 (Q3 FY26) on **Saturday, January 31, 2026**. The board will also consider the declaration of an interim dividend.

## 2) Brokerage Upgrades & Downgrades

The analyst community remains largely **Bullish**, with sentiment bolstered by the Semaglutide approval and strong specialty sales trajectory.

- **Consensus View:** As of January 24, 2026, the consensus rating is a **BUY**.
- **Rating Changes:**

- There have been no immediate downgrades this week.
- Analysts have noted the **Semaglutide approval** as a key medium-term revenue driver, likely to trigger earnings upgrades post-Q3 results.
- **Cautionary Note:** Some desks are awaiting clarity on the **Organon bid valuation**, as large M&A can be dilutive in the short term.

## 3) Other News Impacting SUNPHARMA

- **Competitive Intensity in Obesity Segment:** Alongside Sun Pharma, competitors like **Zydus Lifesciences** and **Alkem Labs** have also received approvals for generic Semaglutide. The "weight-loss" market in India is expected to see a price war post-March 2026, but Sun's early approval and strong distribution network provide a competitive moat.
- **Regulatory Headwinds (Baska Facility):** Investors should remain aware that the **Baska manufacturing facility** received an **Official Action Indicated (OAI)** status from the US FDA in December 2025. While management has stated that supplies continue, this remains a compliance overhang to monitor.
- **Derivatives Activity:** Significant buildup in Open Interest (OI) was observed on Friday, Jan 23, suggesting traders are positioning for high volatility ahead of the Jan 31st earnings and further M&A news.

## 4) Analyst Targets (Consensus Estimates)

The following table summarizes the latest price targets from the analyst community as of this weekend.

Brokerage / Source	Rating	Target Price (INR)	Upside Potential*	Comments
Consensus Mean	BUY	1,965	~20%	Average of 38 analysts
Street High	BUY	2,450	~50%	Bull case based on Specialty expansion
Street Low	HOLD	1,575	-3%	Bear case factoring in reg. risks & M&A debt
Emkay Global	BUY	2,400	~47%	Maintained (Recent Note)
Motilal Oswal	BUY	1,960	~20%	Maintained (Recent Note)
ICICI Direct	BUY	1,965	~20%	Maintained (Recent Note)

# Gemini Stock Analysis Report

---

\*Upside calculated based on current market price of approx. INR 1,632.

**Analyst Take:**"The approval of 'Noveltreat' is a significant positive delta for FY27 estimates. However, the immediate focus is on the Q3 earnings (Jan 31) and clarity on the Organon bid. We recommend a **BUY on Dips** strategy, keeping a close watch on the leverage implications of the potential acquisition."


# **Stock Detailed Analysis Report**

## **SUNPHARMA.NS**

Current Price: ₹1631.90

Generated: 2026-01-24 18:26

# SUNPHARMA.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	8.97%	10.64%
Net Income	Yes	No	14.12%	49.47%
ROE	Yes	No	0.61%	30.45%
EPS	Yes	No	14.29%	49.67%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	7.57%	2.54%
Net Income	No	5.99%	-4.31%
ROE	No	-32.32%	-32.32%
EPS	Yes	-4.72%	1.45%

# SUNPHARMA.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Weakening Leader</b>
RS Score:	49.3/100
:	

## == RS RATIOS ==:

1M RS:	<b>0.992 [Neutral]</b>
3M RS:	<b>1.003 [Leader]</b>
6M RS:	<b>0.996 [Neutral]</b>
1Y RS:	<b>0.926 [Neutral]</b>
:	


## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
:	


## SIGNAL CRITERIA::

✗ Emerging RS:	<b>Not accelerating</b>
✓ Medium-term Lagging:	6M=0.996, 1Y=0.926 ( $\leq 1.0$ )
✗ Performance Improving:	<b>Not improving</b>


**Relative Strength Analysis: SUNPHARMA.NS vs ^CNXPHARMA**  
**Classification: Weakening Leader**  
**Price Performance Comparison (Normalized)**



**RS Ratio Trends (Multiple Timeframes)**




**RS Composite Score Timeline**



## **SUNPHARMA.NS - EMA Crossover Summary**

<b>EMA 20:</b>	1692.38
<b>EMA 50:</b>	1717.76
<b>EMA 200:</b>	1700.35
<b>Trend Status:</b>	<b>Short-term Downtrend</b>
<b>Golden Cross Date:</b>	2025-11-14 00:00:00+05:30
<b>Golden Cross Price:</b>	1757.10


# SUNPHARMA.NS EMA Crossover Analysis



## **SUNPHARMA.NS - Bollinger Bands Summary**

<b>Current Price:</b>	1631.90
<b>Upper Band:</b>	1801.57
<b>Middle Band (SMA 20):</b>	1703.58
<b>Lower Band:</b>	1605.60
<b>%B:</b>	0.1342
<b>Band Width:</b>	0.1150
<b>Status:</b>	Lower Half
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Sell Signal at 2025-12-01 00:00:00+05:30</b>
<b>Recent Signal 2:</b>	<b>Buy Signal at 2026-01-20 00:00:00+05:30</b>
<b>Recent Signal 3:</b>	<b>Buy Signal at 2026-01-21 00:00:00+05:30</b>

## SUNPHARMA.NS Bollinger Bands (20, 2) Analysis




## **SUNPHARMA.NS - Supertrend Summary**

**Status:** DOWNTREND (Sell)

**Supertrend Value:** 1743.57

**Signal Identified On:** 2025-12-18

### Supertrend Analysis for SUNPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## **SUNPHARMA.NS - MACD Summary**

<b>MACD Line:</b>	-32.56
<b>Signal Line:</b>	-22.20
<b>Histogram:</b>	-10.35
<b>Trend:</b>	<b>Bearish</b>
<b>Momentum:</b>	<b>Weakening</b>
<b>Signal:</b>	None

### SUNPHARMA.NS Price






### SUNPHARMA.NS MACD (12, 26, 9)



## **SUNPHARMA.NS - Volatility Squeeze Summary**

<b>BB Width:</b>	0.1150
<b>ATR:</b>	40.7786
<b>Total Signals:</b>	21
<b>Signal 1:</b>	ATR Contraction at 2026-01-02 00:00:00+05:30 (Price: 1728.00)
<b>Signal 2:</b>	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 1728.90)
<b>Signal 3:</b>	ATR Contraction at 2026-01-06 00:00:00+05:30 (Price: 1760.20)
<b>Signal 4:</b>	ATR Contraction at 2026-01-07 00:00:00+05:30 (Price: 1782.60)
<b>Signal 5:</b>	BB Squeeze at 2026-01-14 00:00:00+05:30 (Price: 1700.70)


# SUNPHARMA.NS - Volatility Squeeze Analysis



## **SUNPHARMA.NS - RSI-Volume Summary**

<b>Current RSI:</b>	32.07
<b>Current Volume:</b>	1678658
<b>Volume MA 20:</b>	2176360
<b>Bullish Divergences:</b>	1
<b>Bearish Divergences:</b>	3
<b>Bullish Div 1:</b>	Date: 2025-06-04 00:00:00+05:30, Price: 1659.44
<b>Bearish Div 1:</b>	Date: 2024-04-01 00:00:00+05:30, Price: 1609.07
<b>Bearish Div 2:</b>	Date: 2025-07-30 00:00:00+05:30, Price: 1733.80

# SUNPHARMA.NS RSI-Volume Divergence Analysis



# SUNPHARMA.NS - Volume Analysis

## == VOLUME ANALYSIS ==:

**Status:** 39 Signals Detected

:

**2025-12-24 [-]:** Distribution Day



**2025-12-26 [-]:** Distribution Day

**2025-12-29 [+]:** Selling Exhaustion (Bullish Div)

**2026-01-08 [-]:** Distribution Day

**2026-01-21 [-]:** Distribution Day

## SUNPHARMA.NS - Volume Analysis



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	1774.96	1631.9	2026-01-12
1 Day	DOWNTREND (Sell)	1743.57	1631.9	2025-12-18
15 Min	DOWNTREND (Sell)	1646.12	1631.9	2026-01-23

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	No Signal
1 Day	Bearish	Weakening	No Signal
15 Min	Bearish	Strengthening	No Signal

# SUNPHARMA.NS - 1 Week (Candlestick + EMAs)



# SUNPHARMA.NS - 1 Day (Candlestick + EMAs)



# SUNPHARMA.NS - 15 Min (Candlestick + EMAs)



## Trendlyne Snapshot - SUNPHARMA\_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More ▾

Search Stock, IPO, MF A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [SUN PHARMACEUTICAL INDUSTRIES LTD.](#)

### Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA | BSE: 524715  
Sun Pharmaceutical Live Share Price Today, Share Analysis and Chart

Mid-range Performer In 5 Starfolio Baskets

**1631.90** -2.30 (-0.14%)

**1.8M** NSE+BSE Volume  
NSE 23 Jan, 2026 3:31 PM (IST)

**TRADE STOCK**

Board Meeting The next board meeting for Sun Pharmaceutical is on 31 Jan 2026 for the purpose of Quarterly Results & Interim Dividend [See details](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

Durability score **65.0 /100** Valuation Score **31.0 /100** Momentum Score **45.2 /100** Analyst Price Target **1,965** 1Yr Price target upside is 20%

High Financial Strength Mid-range Performer These stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to ... [View Similar](#) Embed DVM

**14** **7**  
**3** **2**  
 SWOT Analysis

**Check Before You Buy** [VIEW FULL CHECKLIST](#)  
High rank **15** Positive \* **8** Negative 65.2% Pass in checklist

**PE Valuation Check**  
Right Now Undervalued **32.5%** 1 Year Forward Undervalued **47.8%**  
 Sun Pharmaceutical is undervalued at both current PE and future earnings esti... Preset Metrics

**Sun Pharmaceutical Key Metrics**

DVM  
Key Metrics  
Price Chart  
Forecaster  
Financials  
Technicals  
Shareholding  
Deals  
Documents  
Corporate actions  
Company Profile

## Trendlyne Snapshot - SUNPHARMA\_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [SUN PHARMACEUTICAL INDUSTRIES LTD.](#)

**Sun Pharmaceutical Industries Ltd.** ⓘ

NSE: SUNPHARMA | BSE: 524715  
Mid-range Performer ⓘ In 5 Starfolio Baskets

**1631.90** -2.30 (-0.14%)

**1.8M** NSE+BSE Volume  
NSE 23 Jan, 2026 3:31 PM (IST)

Download real time STOCK REPORT

Watchlist Portfolio Alert My Notes TRADE STOCK

Board Meeting The next board meeting for Sun Pharmaceutical is on 31 Jan 2026 for the purpose of Quarterly Results & Interim Dividend See details

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

### Sun Pharmaceutical - SUNPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 38 analysts

Sun Pharmaceutical has a share price target of Rs 1965, revenue growth forecast of 9.2%, and profit growth estimate of 2.8% for FY26, based on top 38 analyst calls.

### Sun Pharmaceutical FORECASTER - Analyst Estimates

[FORECASTER DASHBOARD](#) →

